跳至主要内容
临床试验/JPRN-UMIN000043038
JPRN-UMIN000043038已完成未知

A phase II study of the proportion of criteria for The OncoGuide NCC Oncopanel System for the specimen of unresectable pancreatic cancer obtained by TopGain for EUS-guided fine-needle biopsy - A phase II study of the proportion of criteria for NCC Oncopanel for the specimen of unresectable pancreatic cancer obtained by EUS-FNB

ational Cancer Center Hospital0 个研究点目标入组 33 人开始时间: 2021年1月20日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
33

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)The physician determines that the patient's enrollment in the study is inappropriate

研究者

相似试验

已完成
2 期
Phase II study to determine the optimal number of aspirates during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the diagnosis of sarcoidosisSarcoidosis
JPRN-UMIN000009753agoya Medical Center90
已完成
2 期
A randomized phase II study for the evaluation of T cell depleted non-myeloablative allogeneic stem cell transplantation followed by early consolidation with lenalidomide or lenalidomide combined with bortezomib and subsequent DLI for patients with multiple myeloma in progression or relapse following first line therapyKahlers disease10035227Multiple Myeloma
NL-OMON36688HOVO110
进行中(未招募)
1 期
The effect of anti-latency reversing therapy and broadly neutralizing antibodies on the HIV-1 reservoir in patients on antiretroviral therapy - a randomized trial (ROADMAP)HIV infectionMedDRA version: 20.0Level: LLTClassification code 10020180Term: HIV positiveSystem Organ Class: 100000004848MedDRA version: 20.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestations
EUCTR2015-005238-23-DKRockefeller University30
进行中(未招募)
1 期
A phase 2a, randomized study of the combination of romidepsin and 3BNC117 to evaluate the effects on the HIV-1 reservoir (ROADMAP).
EUCTR2015-005238-23-DEThe Rockefeller University30
已完成
2 期
A phase Ib/II study investigating the combination of RAD001 with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer.10027656Breast cancer
NL-OMON35692ovartis5